Acotec Scientific Holdings Limited (HKG:6669)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
9.80
-0.69 (-6.58%)
Apr 29, 2026, 4:08 PM HKT
27.60%
Market Cap 3.29B
Revenue (ttm) 717.35M
Net Income (ttm) 132.63M
Shares Out 313.39M
EPS (ttm) 0.44
PE Ratio 23.86
Forward PE 21.29
Dividend n/a
Ex-Dividend Date n/a
Volume 292,510
Average Volume 306,330
Open 10.25
Previous Close 10.49
Day's Range 9.72 - 10.36
52-Week Range 7.07 - 15.47
Beta 0.13
RSI 29.30
Earnings Date May 26, 2026

About HKG:6669

Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company’s products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries ... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2011
Employees 645
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6669
Full Company Profile

Financial Performance

In 2025, HKG:6669's revenue was 644.63 million, an increase of 20.72% compared to the previous year's 533.99 million. Earnings were 119.18 million, an increase of 127.97%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.